Misdiagnosis is a Top Concern of Cardiac Patients

Despite many recent advances in cardiovascular diagnosis and treatment, misdiagnosis is still a common concern for patients at risk of heart disease, the leading cause of death in the United States. A complex web of symptoms, circumstances and comorbidities means that it’s not always easy for physicians to correctly identify conditions on the first visit.

Two recent HeartFlow patient stories help illustrate how misdiagnoses can come in a variety of forms: Dennis’ symptoms were originally attributed to asthma, while David visited the ER with chest pain that was initially diagnosed as indigestion.

Fortunately, both patients followed up with their physicians.

David met with his physician, Dr. Gregory Mishkel, at HSHS St. John’s Hospital Prairie Heart Institute, who recognized that his symptoms were unusual. After ordering a Coronary Computed Tomography Angiography scan that showed a significant stenosis, Dr. Mishkel then ordered a HeartFlow Analysis. This provided a comprehensive 3D model of David’s arteries and helped identify the cause of his chest pain.

Similarly, Dennis’ physician, Dr. Peter Maki at Biltmore Cardiology used the HeartFlow Analysis to help identify a blockage in his heart; ultimately, it helped his physician determine that placing a stent was the best treatment option.

A doctor looking at monitors showing heartflow and CT scans Using the HeartFlow Analysis allowed Dennis, David and their physicians to have more information at their disposal to help properly diagnose and treat their coronary artery disease.

In both scenarios, the patients and their physicians had an open dialogue about their symptoms and options for diagnosis.

Watch Patient Stories: Dennis and David

Similar to these examples, regular, open communication from both sides can help prevent misdiagnosis or missed diagnosis. It can also help to combat medical fears and anxieties that keep people from talking to their doctors and seeking the right treatment.

HeartFlow’s recent consumer survey points to how fears can cause people to avoid treatment. The survey found a reluctance among respondents to talk to their doctors about heart disease. Despite 42 percent of Americans knowing they have a family history of heart disease and another 77 percent admitting to worrying about their heart health, most (67 percent) have never sought diagnosis or treatment.

The top concern of survey respondents regarding cardiac care is a misdiagnosis or a missed diagnosis. In fact, more than 1/3 of respondents admitted they have avoided the doctor for fear of what they will find out. This anxiety is understandable, given that other diagnostic tests are less accurate and often miss disease1.

The good news is that new medical technologies are drastically improving the accuracy of diagnosing coronary artery disease.

Tools like the HeartFlow Analysis are helping to improve outcomes1, which in turn can help reduce fears and uncertainty in patients. Dennis and David are just two examples of how things can go right, before it’s too late.

To learn more about The HeartFlow Analysis, click here. See a preview of what the 3D HeartFlow Analysis can look like on mobile here (for iOS only) or on desktop here.

Back to Matters of the Heart

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.